Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
- 1 March 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 7 (3), 348-354
- https://doi.org/10.1158/2326-6066.cir-18-0622
Abstract
The remarkable clinical success of immune-checkpoint inhibitors for the treatment of a growing number of cancer types has sparked interest in the discovery of novel forms of immunotherapy, which may be used alone or in combination. In this context, cytokine-based therapeutics are well poised to play a role in modern cancer therapy. This article focuses on antibody–cytokine fusion proteins (also called “immunocytokines”) as one class of biopharmaceuticals that can substantially improve the therapeutic index and, thus, the applicability of cytokine products. In many preclinical settings, antibodies can be used to preferentially deliver many (but not all) types of cytokines to primary and metastatic tumor lesions. The antibody-based delivery of certain proinflammatory payloads (such as IL2, IL12, and TNF) to the tumor microenvironment can lead to a dramatic potentiation of their anticancer activity. However, although some fusion proteins have advanced to late-stage clinical trials, much work remains to be done in order to fully characterize the mechanism of action and the pharmaceutical potential of immunocytokines in the clinical setting. Various factors contribute to in vivo performance, including the target antigen, the antibody properties, the nature of the payload, the format of the fusion protein, the dose, and schedule, as well as their use in combination with other therapeutic modalities. Protein engineering opportunities and insights in cancer immunology are contributing to the development of next-generation immunocytokine products and of novel therapeutic concepts, with the goal to increase antitumor activity and reduce systemic toxicity (a common problem for cytokine-based biopharmaceuticals).Keywords
Funding Information
- Swiss National Science Foundation (310030B_163479/1)
- ERC (670603)
This publication has 76 references indexed in Scilit:
- Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strainsCancer Immunology, Immunotherapy, 2018
- Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer ModelsClinical Cancer Research, 2017
- Immunocytokines for cancer treatment: past, present and futureCurrent Opinion in Immunology, 2016
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor ModelsClinical Cancer Research, 2016
- Antibody fusions with immunomodulatory proteins for cancer therapyPharmacology & Therapeutics, 2015
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell TransplantationCancer Immunology Research, 2015
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid LeukemiaScience Translational Medicine, 2013
- The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunityBritish Journal of Cancer, 2013
- Quantitation of the Tumor-Targeting Properties of Antibody Fragments Conjugated to Cell-Permeating HIV-1 TAT PeptidesBioconjugate Chemistry, 2002
- The Toxicology of Interleukin-12: A ReviewToxicologic Pathology, 1999